Ph II Cabazitaxel DD Liposarcoma

Status Completed

Clinical Trial Summary

Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying patterns of tumor spread. The optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which are most effective include doxorubicin and ifosfamide, but objective response rates and progression-free survival times remain modest. There is clearly a need to improve treatment options for liposarcoma. Eribulin, a antimicrotubule agent that targets the protein tubulin in cells, interfering with cancer cell division and growth , has demonstrated activity in STS. Therefore, it is reasonable to explore whether other anti-microtubule agent like cabazitaxel have a role in STS. Cabazitaxel has been shown to be a relatively safe, effective and tolerated. This drug has been approved by FDA for prostate cancer. The main objective of this trial is to determine whether cabazitaxel demonstrate sufficient antitumor activity for liposarcoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01913652
Study type	Interventional
Source	European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status	Completed
Phase	Phase 2
Start date	October 2014
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03307616` - Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery	Phase 2
Not yet recruiting	`NCT06389799` - A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)	Phase 2
Recruiting	`NCT05886634` - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma	Phase 2
Completed	`NCT06115681` - Real-world Study of Dedifferentiated Liposarcoma Patients in China
Active, not recruiting	`NCT02846987` - Study of Abemaciclib in Dedifferentiated Liposarcoma	Phase 2
Terminated	`NCT04979442` - Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma	Phase 3
Completed	`NCT02606461` - Selinexor in Advanced Liposarcoma	Phase 2/Phase 3
Active, not recruiting	`NCT04242238` - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	Phase 1
Withdrawn	`NCT00969917` - Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma	Phase 2
Active, not recruiting	`NCT03651375` - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Phase 2
Terminated	`NCT03604783` - Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT05496569` - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma	Phase 2